GlycoVaxyn
Company developing a broad portfolio of bioconjugate vaccines to prevent common bacterial infections using its proprietary glycoprotein technology.
Launch date
Employees
Market cap
-
Enterprise valuation
€173m (Public information from Feb 2015)
Company register number CH-020.3.028.196-4
Zurich Canton of Zürich (HQ)
Financials
Estimates*
EUR | 2015 | 2016 | 2017 | 2018 |
---|---|---|---|---|
Revenues | 4.6m | 4.7m | 4.3m | 4.4m |
% growth | - | 1 % | (8 %) | 4 % |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Spinout | ||
$800k | Series A | ||
N/A | €6.9m | Series A | |
$21.3m | Series B | ||
$190m Valuation: $190m | Acquisition | ||
Total Funding | €27.0m |
Related Content
Recent News about GlycoVaxyn
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.